RxDoctor Payments Data

Jon Davis, MD

Dermatology · Evansville, INNPI 1053549139

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.9% of the total across 452 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 27.2% of the total. Reporting peaked in 2021 at $1,467 and has fallen 68.7% since, to $459 in 2025.

$7,473in general payments, 2019–2025

Across 452 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Novartis$741
  • E.r. Squibb & Sons, L.L.C.$523
  • Sun Pharmaceutical Industries Inc.$511
  • Lilly USA, LLC$314
  • plus $2K from 24 others
$5,707in research payments, 2019–2025

Across 8 payments — averaging $713.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$6K

What the payments were for

  • Food & beverage$7,31298%
  • Education$1602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,473 in reported general payments places this provider in the 65th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana

Medicare billing

Part B allowed, 2024
$994,863
Medicare patients
2,361
Services billed
20,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluocinonide156$6,782
Clobetasol Propionate118$6,245
Ivermectin12$3,623
Fluorouracil53$3,563
Triamcinolone Acetonide298$3,350
Pimecrolimus11$2,976
Tretinoin17$2,700
Doxycycline Hyclate190$2,663
Metronidazole40$2,135
Clindamycin Phosphate44$1,306
Hydrocortisone130$1,067
Ammonium Lactate61$1,031
ValacyclovirValacyclovir Hcl53$875
Doxycycline Monohydrate44$691
Desonide14$632

Paid to pharmacies, not to this prescriber.

Other dermatology in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →